Download presentation
Published byKelly Cunningham Modified over 9 years ago
1
Corporate Presentation J.B.Chemicals & Pharmaceuticals Ltd.
2
Forward Looking Statements
In this presentation we have disclosed forward looking information to enable investors to comprehend our prospects and take informed investment decisions. This presentation and other statements, written and oral, that we periodically make contain forward looking statements that set out anticipated results based on the management’s plan and assumptions. We have tried wherever possible to identify such statements by using words such as ‘anticipate’, ‘aims’ ‘estimate’, ‘expects’, ‘project’, ‘intends’, ‘plans’, ‘believes’, and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward looking statements will be realized, although we believe we have been prudent in assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Everybody should bear this in mind.
3
COMPANY BUSINESS UNITS MANUFACTURING STRATEGY
4
Background The name J. B. Chemicals & Pharmaceuticals Ltd. was christened after Mr. J. B. Mody who is the Chairman and founder of JBCPL JBCPL is a leading and publicly traded pharmaceutical company in India Leading by the vision and dynamism of Mr. J. B. Mody, a visionary and pioneer with an experience of over five decades in the pharmaceutical industry, the group has diversified into different sectors
5
Brief on JBCPL Incorporated in 1976 with an IPO in 1985
Listed on the BSE and NSE with a market cap of USD 110 million Manufacturing facilities in Gujarat and Maharashtra for formulations and API Subsidiary in South Africa and Russia Total employee strength of 2900
6
2012-13 Quarterly Revenues & Profits
Rs. in crores Financial year: April 2012 – March 2013
7
2012-13 Quarterly Revenues & Profits
USD in millions Financial year: April 2012 – March 2013
8
Annual Revenues & Profits
Rs. in crores * Divestment of Russia-CIS OTC business to J&J
9
Annual Revenues & Profits
USD in millions * Divestment of Russia-CIS OTC business to J&J
10
Strategic Business Units
INDIA Prescription and Hospital CONTRAST MEDIA GLOBAL ANDA Contract Manufacturing Branded Generics OTC Contrast Media API RUSSIA & CIS OTC, Prescription, Hospital JBCPL INDIA 40% CONTRAST MEDIA 5% GLOBAL 30% API 7% RUSSIA & CIS 18% BUSINESS DEVELOPMENT
11
India Prescription products
Domestic market estimated at about USD 11 billion and growing by about 18% as per ORG JBCPL Ranked 35th (ORG) with 3 brands featuring in top 300 brands reported by ORG JBCPL continued consolidation process during , and adopted key brands focus marketing strategy Top 4 therapeutic segments: Gastro-enterology, Cardiovascular, Pain management and Antibiotic Acute segment contributes about 82% of total sales Current field force: 1100 sales representatives
12
India Growth Plan JBCPL has placed increased concentration on domestic market for next level growth. Increase in field force New product introductions JBCPL plans to increase field force to 1500 in This is aimed at strengthening rural market presence with strength increase in urban market too
13
Contrast Media – niche focus
Contrast Media Products Caters to niche radio-diagnostic products used in CT Scan, MRI and Cath Lab through 30 sales representatives Iopamidol Iohexol Gadopentetate dimeglumine Diatrizoate Meglumine In-licensed a new Ultrasound Contrast Imagining product (Definity) of Lantheus Medical Imaging Inc. from USA
14
Russia/Ukraine/CIS Latvia Estonia Lithuania Byelorussia Ukraine
Maldova Russia Georgia Armenia Kazakhstan Azerbaijan Turkmenistan Uzbekistan Mongolia Kyrghyztan Tajikistan
15
Russia/Ukraine/CIS Russian market is estimated to be about US $12 billion at retail level, growing by about 7% in value annually JBCPL is ranked amongst the top Indian companies Entered Russia in 1992 Offices in Russia/Ukraine and some CIS countries
16
Russia/Ukraine/CIS Divested OTC portfolio to Johnson & Johnson in May 2011 Contract manufacturing for J&J for these OTC products Prescription business continues through wholly owned subsidiary in Russia
17
Global Contract Manufacturing and Product pipeline will increase to fuel growth Activity wise breakup
18
Global Top markets breakup
19
South Africa In 2007, JBCPL has made strategic investment in Biotech Laboratories (Pty) Ltd., South Africa, a BEE marketing and sales, marketing and distribution company Have 49% equity stake with preference shares to take it to 51% Robust products pipeline to strengthen direct business with Biotech
20
Contract Manufacturing
Contract Manufacturing (Clear Focus) Projects awarded by multinationals globally More than 10 clients Tailor made services for customers Injectables Vials Ampoules Form Fill Sealed Semi-solid Creams Ointments Gels Solid Tablets Lozenges Herbal Medicated
21
Contract Manufacturing
Complete package New Product development Analytics services Technology transfer Regulatory support Manufacturing
22
Lozenges Lozenges, a JBCPL niche strength, has excellent scope in global market Medicated and Herbal We manufacture lozenges under our own brands and private label Private label lozenges for leading UK/EU, South African, Australian and Canadian companies.
23
API Business JBCPL manufactures 2 APIs one of the largest manufacturer of Diclofenac Sodium (BP, EP, USP) and Nifedipine
24
Brands | Assets Zecuf herbal Cough and Cold Nicardia (Nifedipine)
Anti-hypertensive Metrogyl (Metronidazole) Anaerobicide Rantac (Ranitidine) Anti-peptic ulcerant Panum (Pantaprazole) OF (Ofloxacin) Antibiotic Dicloran (Diclofenac Sodium) NSAID
25
Manufacturing Facilities
At Daman Located at Kadaiya, Daman Manufactures lozenges and tablets Lozenges approved by: UK MHRA TGA Australia MCC South Africa FDB Ghana
26
Manufacturing Facilities
At Gujarat Plant TI – 10 Located at Panoli Manufactures tablets Facility approved by US FDA UK MHRA TGA Australia MCC South Africa INVIMA Colombia Germany (EU-GMP)
27
Manufacturing Facilities
At Gujarat Plant IV -17 Located at Panoli Manufactures injectables - FFS, vials and ampoules Facility approved by: MCC South Africa INVIMA Colombia
28
Manufacturing Facilities
At Gujarat Plant IV -14 Located at Panoli Manufactures injectables, ointments & cold rubs Facility approved by: MCC South Africa NDA Uganda Pharmacy Board Tanzania INVIMA Colombia
29
Manufacturing Facilities
At Gujarat Plant L-6 Located at Panoli Manufactures herbal liquids
30
Manufacturing Facilities
At Gujarat Plant D 9 Located at Panoli Manufactures Diclofenac API Facility approved by: US FDA Germany EU-GMP
31
Manufacturing Facilities
At Gujarat Plant UM 12 Located at Ankleshwar Manufactures tablets and liquids Facility approved by: NDA - Uganda (Tablets & liquids) Pharmacy Board - Tanzania (liquid)
32
Strategy ANDA: Develop and manufacture products for USA market
Contract Manufacturing: Increase our customer base by providing quality products at cost effective prices Russia marketing: Form JV/Partnerships for marketing New Territories: Expand into newer territories through partnerships Capacities: Enhance capacities in for ANDA and contract manufacturing tablets Injectables Lozenges
33
Thank You J.B.Chemicals & Pharmaceuticals Ltd.
| J.B.Chemicals & Pharmaceuticals Ltd.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.